Who Owns LILLY ELI & CO Stock? 4,264 Institutional Holders — Q4 2025 13F Data

Based on SEC Form 13F filings for Q4 2025, filed February 2026.

As of Q4 2025, 4,264 institutional funds hold $LLY, with Lilly Endowment retaining the largest disclosed stake at $99.08B — making Eli Lilly one of the most institutionally held pharmaceutical stocks in the market.

LILLY ELI & CO Institutional Ownership — Q4 2025 Overview

The Q4 2025 13F cycle delivered a striking data point for $LLY: total institutional holders surged by +516 funds in a single quarter — the largest jump across any of the five most recent reporting periods. That brought the total to 4,264 funds reporting a position, up from 3,748 in Q3 2025. Combined disclosed market value across all institutional holders reached $846.19B.

To put that jump in context: the prior four quarters averaged a net change of just +15 funds per period. A +516 surge is not a statistical blip — it reflects a meaningful broadening of institutional participation in $LLY's equity ownership structure. Whether that reflects index rebalancing, active conviction, or both is the critical question this data helps answer.

The five-quarter ownership trend, sourced from 13Foresight's institutional database and cross-referenced against SEC EDGAR 13F filings, tells a clear directional story: institutional consensus around Eli Lilly has been forming steadily, with Q4 2025 marking an acceleration.

Who Owns the Most $LLY?

Lilly Endowment Inc holds the single largest disclosed position in $LLY at $99.08B — a structural anchor stake that reflects the endowment's historic ties to the Lilly family rather than active portfolio management. This type of concentrated, mission-linked ownership typically signals long-term price stability at the ownership base, but also means the holder is less responsive to near-term earnings catalysts. Its modest -3.5% reduction this quarter is worth watching, though it does not yet constitute a meaningful exit signal.

BlackRock, Inc. holds the second-largest position at $71.78B, up +1.5% quarter-over-quarter. As the world's largest asset manager, BlackRock's presence is primarily index-driven — meaning its $LLY stake reflects Eli Lilly's weighting in benchmarks like the S&P 500 and Russell 1000. Index ownership of this scale provides structural demand: as long as $LLY remains a large-cap holding, BlackRock's position grows proportionally. A +1.5% expansion signals the stock's market cap-weighted position in those benchmarks has increased, a quiet but meaningful form of institutional validation.

PNC Financial Services Group, Inc. sits third with $55.17B in disclosed $LLY exposure, essentially unchanged at -0.1% QoQ. A position of this scale held flat by a financial services firm — rather than a pure asset manager — often reflects custodial or fiduciary mandates rather than a directional alpha call. That said, the sheer size of PNC's stake places it among the five largest institutional holders of any single pharmaceutical equity in the current 13F universe.

Biggest Moves This Quarter: Who's Adding and Who's Trimming

The most aggressive capital deployment into $LLY this quarter came from JPMorgan Chase & Co, which expanded its position by +26.6% to reach $13.97B — a high-conviction accumulation signal from one of the most data-intensive allocation teams on Wall Street. Jane Street Group added +24.8%, bringing its stake to $5.37B, while Jennison Associates grew its position +22.3% to $5.52B. These three names represent very different investor archetypes — a universal bank, a quantitative market maker, and a growth-oriented active manager — yet all three are leaning in simultaneously. HIGH CONVICTION

On the trimming side, Primecap Management Co cut its $LLY position by -14.2%, followed by Citadel Advisors at -12.0% and Goldman Sachs Group at -11.9%. Wellington Management Group reduced by -8.3% and Bank of America trimmed -8.7%. These are not marginal position adjustments — they represent meaningful portfolio reallocation decisions by managers with deep pharmaceutical sector expertise.

FMR LLC (Fidelity) expanded its position by +6.4% to $27.64B, the fourth-largest disclosed stake — a signal of ongoing active conviction from one of the most influential growth-equity managers in the market. GROWING INTEREST

What $LLY's Institutional Ownership Pattern Signals

The Q4 2025 data presents a genuinely nuanced picture for LLY institutional ownership. On the surface, a +516 fund surge and $846.19B in total disclosed institutional value reads as an unambiguously bullish smart money signal. But the directional split among major holders — 8 adding, 11 reducing among the top 20 — adds important texture to that headline number.

The most significant bullish signal comes from the character of the buyers. JPMorgan, Jane Street, and Jennison Associates are not passive participants — they are active, research-intensive capital allocators making deliberate portfolio decisions. When three structurally different institutions all increase exposure above +20% in the same quarter, it reflects a shared thesis: Eli Lilly's GLP-1 and oncology pipeline represents multi-year earnings durability that justifies current valuations. That is an institutional consensus forming in real time.

The trimming activity, however, deserves equal attention. Primecap (-14.2%), Citadel (-12.0%), and Goldman Sachs (-11.9%) are not noise traders — they are disciplined risk managers. Their reductions may reflect valuation discipline at current price levels, sector rotation, or portfolio rebalancing rather than a loss of fundamental conviction. The equity ownership structure of $LLY remains heavily institutional, and the net fund count expansion confirms that new capital is entering even as some established holders take profits. WATCH LIST

For investors tracking LLY hedge fund holders specifically: the data shows a split between active accumulators and profit-takers. The surge in total fund count — ↑ +516 funds QoQ — suggests the broadening institutional participation is coming primarily from smaller and mid-size asset managers entering new positions, while the largest sophisticated managers are pruning at the margin. This pattern is typical in stocks where valuation has run significantly ahead of near-term earnings visibility, yet long-term conviction in the underlying business thesis remains high.

Data sourced from SEC Form 13F filings. 13F data reflects long equity positions held at quarter-end and is filed 45 days after quarter close. This article is for informational purposes only and does not constitute investment advice.